ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIdeal ganciclovir dosing for the treatment of cytomegalovirus and herpesvirus in children receiving continuous renal replacement therapy (CRRT) is unknown. Available literature regarding ganciclovir pharmacokinetics (PK) in children suggests high interpatient variability and risk of underexposure. Therapeutic drug monitoring (TDM) may be of benefit in pediatric patients to optimize dosing, with a 24-hour area under the curve (AUC
methodsThis retrospective, single-center cohort study reviewed the electronic medical records of patients 17 years of age or younger who received ganciclovir treatment along with drug concentration monitoring in the pediatric intensive care unit (PICU) between July 2022 and July 2023. Data included ganciclovir dose, PK parameters, CRRT modality, as well as effectiveness and safety outcomes.
resultsA total of 5 patients (median age, 12 years; IQR, 8.5-14.5) received ganciclovir in the PICU. Patients received continuous venovenous hemodiafiltration at a median clearance rate of 1928 mL/1.73m
conclusionThe results of this study show variable ganciclovir drug exposure in critically ill pediatric patients receiving CRRT. Further study is needed to determine appropriate ganciclovir dosing and the role of TDM in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.